Physician profile
Mohsin Ahmad
NPI 1700127917
$6,842.29
in general payments reported to CMS, 2019-2025
35 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $230 · 2021: $14.16 · 2022: $679 · 2023: $1,326 · 2024: $1,560 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,398 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,398.09 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $854.27 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $810.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $780.18 | 2019-2025 | |
| Abbvie INC. | $651.57 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $529.38 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $498.90 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $402.83 | 2019-2024 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $391.92 | 2019-2024 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $203.08 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.85 | 2019-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $190.06 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $166.07 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Exact Sciences Corporation | $130.21 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $125.30 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Shield Therapeutics INC | $124.80 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $114.50 | 2024-2025 | Voquezna |
| Dexcom, INC. | $109.16 | 2022-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.38 | 2019 | |
| Axsome Therapeutics, INC. | $66.05 | 2025 | Symbravo |
| Amarin Pharma, INC. | $64.62 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $41.66 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $32.87 | 2023 | Freestyle Libre 3 |
| Corium, LLC | $28.57 | 2022 | |
| Shire North American Group INC | $25.64 | 2019 | |
| Pulmonx Corporation | $25.60 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Teva Pharmaceuticals USA, INC. | $25.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.87 | 2019 | |
| Optinose US, INC. | $22.97 | 2025 | |
| Dynavax Technologies Corporation | $22.93 | 2024 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $21.93 | 2020 | |
| Insulet Corporation | $19.62 | 2019 | |
| Viatris Specialty LLC | $18.90 | 2025 | Yupelri |
| Currax Pharmaceuticals LLC | $15.34 | 2025 | Onzetra Xsail, Contrave |
| Amneal Pharmaceuticals LLC | $13.32 | 2024 | Unithroid |
| Nalpropion Pharmaceuticals LLC | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.